MétaCan
← tous les travaux

Clinical and Immunological Factors in Emphysema Progression: Five-Year Prospective Longitudinal Exacerbation Study of Chronic Obstructive Pulmonary Disease (LES-COPD)

2015· article· en· 49 citations· W2186706438 sur OpenAlex· 10.1164/rccm.201504-0736oc

Pourquoi ce travail est-il dans la base ?

Une base qui oublie comment elle a trouvé un travail ne peut pas être vérifiée. Voici les voies qui ont admis celui-ci.

Affiliation canadienneUne personne signataire a déclaré un établissement canadien. C'est la seule voie dont dispose la base habituelle.

Le tri à trois modèles

les 1 000 travaux triés →

Les trois modèles l'ont jugé hors champ.

strate : aff_core · poids de sondage : 5595.24 (l'échantillon est stratifié ; tout taux calculé sans le poids est faux)
Claude Opus 4.8OUT
genre : empirical
porte sur le Canada: non
confiance: high

Longitudinal clinical cohort study of emphysema progression in COPD.

GPT-5.6 (high)OUT
genre : empirical
porte sur le Canada: non
confiance: high

This prospective study examines emphysema progression and clinical biomarkers, not research.

Grok 4.5OUT
genre : empirical
porte sur le Canada: non
confiance: high

Longitudinal clinical COPD/emphysema study, not metaresearch.

Résumé

RATIONALE: Cross-sectional studies of T-cell responses to self-antigens correlate with baseline emphysema severity. OBJECTIVES: We investigated whether clinical and/or immunological factors could predict disease progression, such as emphysema, FEV1, and 6-minute-walk distance (6MWD), in former and active smokers in a 5-year prospective study. METHODS: We recruited 224 ever smokers over 40 years of age and with greater than a 15 pack-year smoking history. MEASUREMENTS AND MAIN RESULTS: Repeated spirometry, 6MWD, and peripheral blood T-cell cytokine responses to lung elastin fragments were measured. Baseline and repeat chest computed tomography (CT) scans (34 to 65 mo apart) were used to quantify emphysema progression. Of the 141 ever-smokers with baseline and repeat CT scans, the mean (SD) annual rate of change in percent emphysema was +0.46 (0.92), ranging from -1.8 to +4.1. In multivariable analyses, the rate of emphysema progression was greater in subjects who had lower body mass index (BMI) (+0.15 per 5-unit decrease in BMI; 95% confidence interval, +0.03 to +0.29). In active smokers, increased IFN-γ and IL-6 T-cell responses had a positive association with the annual rate of emphysema progression. Male sex and IL-6 T-cell responses to elastin fragments were significantly associated with annual 6MWD decline, whereas IL-13 was associated with an increase in annual 6MWD. CONCLUSIONS: The rate of emphysema progression quantified by CT scans among ever-smokers was highly variable; clinical factors and biomarkers explained only some of the variability. Aggressive clinical care that targets active smokers with autoreactive T cells and low BMI may temporize progression of emphysema.

Conservé avec la notice de tri, où il sert de preuve aux étiquettes ci-dessus.

La notice

Revue
American Journal of Respiratory and Critical Care Medicine
Thématique
Chronic Obstructive Pulmonary Disease (COPD) Research
Domaine
Medicine
Établissements canadiens
Vancouver General HospitalUniversity of British Columbia
Organismes subventionnaires
National Center for Advancing Translational SciencesNational Center for Research ResourcesNational Heart, Lung, and Blood InstituteNational Institutes of HealthU.S. Department of Veterans Affairs
Mots-clés
MedicineSpirometryInternal medicineBody mass indexCOPDProspective cohort studyExacerbationConfidence intervalCardiologyAsthma
Résumé présent dans OpenAlex
oui